Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin-4 IgG seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) are generally considered to be relapsing disorders, without clinical progression or subclinical disease activity outside of clinical relapses, in contrast to multiple sclerosis (MS). With advances in the diagnosis and treatment of these conditions, prolonged periods of remission without relapses can be achieved, and the question of whether progressive disease courses can occur has re-emerged. In this review, we focus on studies exploring evidence for and against relapse-independent clinical progression and/or subclinical disease activity in patients with MOGAD and AQP4-IgG+ NMOSD.

髓鞘少突胶质细胞糖蛋白抗体病 (MOGAD) 和水通道蛋白-4 IgG 血清反应阳性视神经脊髓炎谱系障碍 (AQP4-IgG+ NMOSD) 通常被认为是复发性疾病，与多发性硬化症相比，在临床复发之外没有临床进展或亚临床疾病活动。多发性硬化症）。随着这些疾病的诊断和治疗的进步，可以实现长时间的缓解而不复发，并且是否会出现进行性疾病过程的问题再次出现。在这篇综述中，我们专注于探索支持和反对 MOGAD 和 AQP4-IgG+ NMOSD 患者的不依赖于复发的临床进展和/或亚临床疾病活动的证据的研究。